Hugel, Inc. 145020.KQ · Stock Open Hugel, Inc. in new tab
Hugel, Inc. Analysis (145020.KQ)
Is Hugel, Inc. a good investment? Hugel, Inc. (145020.KQ) is currently trading at 248500.00 KRW. Market analysts have a consensus price target of 357000.00 KRW. This suggests a potential upside from current levels.
Earnings Schedule: Hugel, Inc. is expected to release its next earnings report on Aug. 18, 2026.
Investor FAQ
Does Hugel, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Hugel, Inc.?
Hugel, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 18, 2026.
Company Profile
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.
| Split Date | Split Ratio to 1 |
|---|---|
| Dec. 26, 2019 | 0.847000 |
| July 8, 2020 | 3.000000 |
| Jan. 26, 2021 | 0.985400 |
Community Discussion